Scientific Publications by FDA Staff
Dev Biol 2007 Oct 1;310(1):129-39
Vg1 has specific processing requirements that restrict its action to body axis patterning centers.
Thomas JT, Moos M Jr
Moos M (reprint author), US FDA, Div Cellular & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA US FDA, Div Cellular & Gene Therapy, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA
Unlike most transforming growth factor-beta (TGF-beta) superfamily members, Vg1 has been shown not to produce gross phenotypic alterations in Xenopus embryos when overexpressed by mRNA injection. Experiments with artificial chimeric constructs and a recently identified second allele of Vg1 suggest that this may be due to unusually stringent requirements for proteolytic processing. We provide biological and biochemical evidence that cleavage by two distinct proteolytic enzymes is required for effective activation of Vg1. We demonstrate a tightly restricted overlap in expression patterns of Vg1 with the proteases required to release the mature peptide. The data presented may account for the long-standing observation that the vast majority of Vg1 protein, in vivo, is present in its unprocessed form. Taken together, these observations provide a plausible mechanism for local action of Vg1 consistent with requirements imposed by current models of pattern formation in the developing body axis.
|Category: Journal Article|
|PubMed ID: #17707366|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2011-10-04||Entry Last Modified: 2012-08-29|